Cargando…

Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism

Detalles Bibliográficos
Autores principales:	Lucijanic, Marko, Krecak, Ivan, Soric, Ena, Sedinic, Martina, Sabljic, Anica, Derek, Lovorka, Jaksic, Ozren, Kusec, Rajko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629336/ https://www.ncbi.nlm.nih.gov/pubmed/34845183 http://dx.doi.org/10.1038/s41408-021-00585-2

Ejemplares similares

PB2194: HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME
por: Lucijanic, Marko, et al.
Publicado: (2023)

Comparison of IMPROVE, modified IMPROVE, IMPROVEDD, Padua and CHA2DS2-VASC risk scores for venous and arterial thrombotic events prediction in hospitalized COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2022)

P1691: COMPARISON OF IMPROVE, MODIFIED IMPROVE, IMPROVEDD AND PADUA RISK SCORES FOR VENOUS THROMBOEMBOLISM PREDICTION IN HOSPITALIZED COVID-19 PATIENTS
por: Lucijanic, M., et al.
Publicado: (2022)

Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

P1051: CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms
por: Krečak, Ivan, et al.
Publicado: (2023)

More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
por: Lucijanic, Marko, et al.
Publicado: (2021)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

PB2219: POLYPHARMACY AND DRUG-TO-DRUG INTERACTIONS MAY HAVE A NEGATIVE EFFECT ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
por: De Stefano, Valerio, et al.
Publicado: (2018)

Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients
por: Pejša, Vlatko, et al.
Publicado: (2017)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

P1592: MATCHED CONTROL COMPARISON OF SURVIVAL OF HOSPITALIZED COVID-19 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES, DATA FROM A LARGE TERTIARY CENTER REGISTRY
por: Lucijanic, M., et al.
Publicado: (2022)

Ruxolitinib withdrawal due to the COVID-19
por: Lucijanic, Marko, et al.
Publicado: (2021)

Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms
por: Torres, Cláudia, et al.
Publicado: (2013)

Anemia with thrombocytosis in an elderly male: a case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Kumar, Ashutosh, et al.
Publicado: (2018)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study
por: Holik, Hrvoje, et al.
Publicado: (2023)

Red cell distribution width is a potent prognostic parameter for in-hospital and post-discharge mortality in hospitalized coronavirus disease 2019 patients: a registry-based cohort study on 3941 patients
por: Lucijanić, Marko, et al.
Publicado: (2022)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia
por: Langabeer, Stephen E.
Publicado: (2020)

Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Katiyar, Vatsala, et al.
Publicado: (2019)

A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
por: Lazo-Langner, Alejandro, et al.
Publicado: (2019)

P1040: HIGHER ESTIMATED PLASMA VOLUME STATUS IS ASSOCIATED WITH INCREASED THROMBOTIC RISK AND IMPAIRED SURVIVAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Lucijanic, M., et al.
Publicado: (2022)

P1039: PALPABLE SPLEEN SIZE IS PROGNOSTIC IN PRIMARY BUT NOT SECONDARY MYELOFIBROSIS
por: Lucijanic, M., et al.
Publicado: (2022)

Asymptomatic deep vein thromboses in prolonged hospitalized COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2021)

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis
por: Aoyama, Yumi, et al.
Publicado: (2019)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Duffy‐null erythrocyte phenotype and the risk of thrombotic events in essential thrombocythemia
por: Krecak, Ivan, et al.
Publicado: (2023)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Essential Thrombocytosis-Associated Thromboembolism in the Abdominal Aorta
por: Chong, Byung Kwon, et al.
Publicado: (2016)

The Risk of Venous Thromboembolism in Neuroendocrine Neoplasms
por: Wójcik-Giertuga, Monika, et al.
Publicado: (2023)

P1035: RING SIDEROBLASTS <15% WAS AN INDEPENDENT RISK FACTOR FOR MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH SF3B1 MUTATION AND THROMBOCYTOSIS
por: LI, Fuhui, et al.
Publicado: (2023)

Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype
por: Heibl, Sonja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_poi9936uhqco7buqhllubht21j